Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Kiniksa Pharmaceuticals Ltd
NASDAQ:KNSA
Price:
46.34
USD
0.06%
Market Closed
Market Cap:
$3.5B
Balance Sheet
Balance Sheet Decomposition
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
Balance Sheet Decomposition is not available for
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
Balance Sheet
Kiniksa Pharmaceuticals Ltd
Kiniksa Pharmaceuticals Ltd
Currency: USD
| Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
56
|
46
|
72
|
47
|
114
|
123
|
123
|
108
|
184
|
166
|
|
| Cash Equivalents |
56
|
46
|
72
|
47
|
114
|
123
|
123
|
108
|
184
|
166
|
|
| Short-Term Investments |
0
|
0
|
235
|
187
|
209
|
60
|
68
|
98
|
60
|
248
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
4
|
20
|
21
|
42
|
16
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
4
|
20
|
21
|
42
|
16
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
4
|
22
|
31
|
26
|
55
|
|
| Other Current Assets |
0
|
2
|
6
|
8
|
10
|
7
|
11
|
18
|
20
|
43
|
|
| Total Current Assets |
56
|
47
|
314
|
242
|
333
|
196
|
243
|
276
|
332
|
527
|
|
| PP&E Net |
0
|
0
|
6
|
8
|
11
|
8
|
7
|
13
|
11
|
12
|
|
| PP&E Gross |
0
|
0
|
6
|
8
|
11
|
8
|
7
|
13
|
11
|
12
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
2
|
5
|
6
|
7
|
8
|
8
|
7
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
19
|
18
|
17
|
16
|
15
|
|
| Other Long-Term Assets |
0
|
0
|
2
|
5
|
6
|
9
|
191
|
220
|
221
|
209
|
|
| Total Assets |
57
N/A
|
48
-16%
|
322
+578%
|
255
-21%
|
350
+37%
|
233
-33%
|
460
+97%
|
526
+14%
|
581
+10%
|
764
+32%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
0
|
1
|
11
|
6
|
1
|
2
|
8
|
8
|
2
|
2
|
|
| Accrued Liabilities |
2
|
16
|
31
|
22
|
31
|
41
|
33
|
47
|
83
|
115
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
2
|
6
|
9
|
16
|
22
|
|
| Total Current Liabilities |
2
|
17
|
43
|
28
|
32
|
45
|
47
|
64
|
101
|
139
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
1
|
6
|
3
|
17
|
24
|
41
|
57
|
|
| Total Liabilities |
2
N/A
|
17
+657%
|
43
+145%
|
29
-32%
|
38
+29%
|
48
+27%
|
64
+33%
|
87
+38%
|
142
+62%
|
196
+38%
|
|
| Equity | |||||||||||
| Common Stock |
80
|
120
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Retained Earnings |
26
|
91
|
194
|
356
|
518
|
675
|
492
|
478
|
521
|
462
|
|
| Additional Paid In Capital |
0
|
1
|
474
|
582
|
829
|
861
|
888
|
917
|
960
|
1 030
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
54
N/A
|
30
-44%
|
279
+828%
|
225
-19%
|
312
+38%
|
185
-41%
|
396
+114%
|
439
+11%
|
438
0%
|
568
+29%
|
|
| Total Liabilities & Equity |
57
N/A
|
48
-16%
|
322
+578%
|
255
-21%
|
350
+37%
|
233
-33%
|
460
+97%
|
526
+14%
|
581
+10%
|
764
+32%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
48
|
48
|
50
|
55
|
68
|
69
|
70
|
70
|
73
|
76
|
|
Switch to:
Switch to:
See Also
Discover More
